Amyotrophic Lateral Sclerosis (ALS)

Emotional Expression Medication Approved for Use in ALS

The U.S. Food and Drug Administration (FDA) has approved Nuedexta for "pseudobulbar affect" (PBA), a neurologic condition that sometimes occurs in people with amyotrophic lateral sclerosis (ALS) and involves episodes of involuntary emotional expression out of proportion to or distinct from the person's actual emotional state. The approval was announced by Nuedexta's developer, Avanir Pharmaceuticals, Oct. 29, 2010.

ALS Stem Cell Trial is Moving Forward

The Maryland biotherapeutics company Neuralstem will move its clinical trial of neural stem cells in people with amyotrophic lateral sclerosis (ALS) into its next stage, following a thumbs-up from the trial's safety monitoring board, the company announced Oct. 18, 2010. (See Neuralstem Updates ALS Clinial Trial Progress.)

National ALS Registry Now Open

After two years of laying the groundwork, the Agency for Toxic Substances and Disease Registry (ATSDR) has opened its National ALS Registry to collect information from people living with ALS.

Scientists at the ATSDR, which is part of the Centers for Disease Control and Prevention in Atlanta, hope registry data will provide insight into the causes of, and potential treatments for, ALS.

Misfolded SOD1 Found in Sporadic ALS Samples

A new study suggests misfolding of the SOD1 protein may be a common contributor not only to familial (inherited) amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene but to the more common sporadic (noninherited) form of the disease as well.

ALS TDI Conference Summarizes ALS Research Progress

Themes discussed throughout the research symposium included ALS genetics, clinical trials, the role of the immune system in disease onset and progression, biomarkers, and the use of stem cells in ALS therapeutics.

Diaphragm Pacing System Awaiting FDA Approval for ALS

The Synapse Biomedical NeuRx Diaphragm Pacing System (DPS), a device that stimulates the respiratory diaphragm with electrical signals, has received Humanitarian Use Device designation from the U.S. Food and Drug Administration (FDA), allowing it to be used by people with amyotrophic lateral sclerosis (ALS) who have a “stimulatable” diaphragm and are experiencing chronic breathing problems.

MDA/ALS Research Center Earns Prestigious Award

The Forbes Norris MDA/ALS Research and Treatment Center in San Francisco has received Program of the Year honors from the California Speech-Language-Hearing Association (CSHA).

ALS Research Briefs

Trial results announced for drug for laughing/crying jags

Deshae Lott Scholarships Awarded

Three accomplished scholars determinedly pursuing their educations while living with neuromuscular disease are the first winners of the CMMS Deshae Lott Ministries outreach program scholarships.

Deshae Lott Scholarships Awarded

Three accomplished scholars determinedly pursuing their educations while living with neuromuscular disease are the first winners of the CMMS Deshae Lott Ministries outreach program scholarships.

“We were so impressed,” with the winning candidates, said Deshae Lott, 39, a teacher and minster from Bossier City, La., who founded the nonprofit that bears her name. “These three show great strength of mind and character. Each of them strives to maximize within their limitations.”

Pages